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reativecommons.org/licenses/by/4.0/).a b s t r a c tObjectives: To assess the performance of LIAISON
s
BRAHMS PCT
s
II GEN (DiaSorin, Salu-
ggia, Italy) in procalcitonin (PCT) determination by comparing it to the assay reference
method B R A H M  S PCT KRYPTOR (Thermo Fisher Scientific Clinical Diagnostics,
Hennigsdorf, Germany) and assessing its ability to discriminate between healthy subjects
and patients with suspected infection.
Methods: Diagnostic performance was evaluated on: a) 193 selected samples covering the
assay range, whose procalcitonin levels were already evaluated with the B R A H M  S
PCT
s
KRYPTOR; b) prospective samples: 150 apparently healthy specimens obtained from
a blood bank, 161 hospitalized patients (not with specific pathologies), 243 apparently
healthy children.
Results: The comparison of LIAISON
s
BRAHMS PCT
s
II GEN to the reference method
B R A H M  S PCT KRYPTOR yielded high correlation coefficients: slope of Deming fit
equal to 1.04 (95% CI: 0.99–1.09) with an intercept equal to 0.05 (95% CI: 0.09 to 0.19)
and a high concordance (98.4% (95% CI: 95.5–99.7%)) at the 0.5 ng/mL cut-off. Moreover,
the results obtained using prospective samples showed: (i) no samples with PCT
concentration 40.5 ng/mL (cut-off) for the apparently healthy adults (highest
value¼0.033 ng/mL, 95th percentile and 97.5th percentile o0.02 ng/mL); (ii) 2 samples
40.5 ng/mL for hospitalized patients (highest value¼0.715 ng/mL, 95th percentile:
0.054 ng/mL; 97.5th percentile: 0.088 ng/mL); (iii) 3 samples 40.5 ng/mL for the healthy
children population (highest value¼0.713 ng/mL, 95th percentile: 0.155 ng/mL; 97.5th
percentile: 0.275 ng/mL).
Conclusion: The fully automated LIAISON
s
BRAHMS PCT
s
II GEN agrees well with the
reference method and is suitable for early diagnosis of sepsis, severe bacterial infection
and guiding antibiotic therapy.
& 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the last two decades, an increasing number of studies have evidenced the diagnostic and prognostic role of pro-
calcitonin (PCT) in discriminating between bacterial, viral or other non-bacterial infection, sepsis and systemic inflammation
[1] across a variety of clinical scenarios, in both adult and pediatric populations [2].
PCT concentrations increase at the onset of bacterial infection and correlate with the severity of infection. In healthy
adults, plasma PCT concentrations generally remain below 0.05 ng/mL and rapidly increase within 2–4 h in case of systemic
bacterial infection (o0.25 to o0.5 ng/mL), sepsis (40.5 to 42 ng/mL) and some non-infectious conditions (including
trauma, surgery, burns, hyperthermia and neoplasms), remaining high until recovery (Table 1) [3–5]. Slightly higher PCTr B.V. This is an open access article under the CC BY license
Table 1
PCT concentrations cut-off reference values.
PCT serum level Reference value
0.05 ng/mL Healthy
o0.25–0.5 ng/mL Systemic bacterial infection
0.5 ng/mL Local infection
40.5 to 42 ng/mL Sepsis and non-infectious conditions
Z2 to r10 ng/mL Severe sepsis
10 ng/mL Sepsis shock
Such reference values must be considered together with individual patient's clinical conditions. Because PCT increase is associated with severity of systemic
inflammatory response, low PCT values do not exclude for local bacterial infection, or viral infection. PCT levels can also be influenced by other non-
infectious conditions such as severe trauma, autoimmune disorders, pancreatitis, renal dysfunction; hence reference ranges must be taken from current
literature for specific condition or study population [adapted from 4,5].
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of inflammatory response, it is generally accepted that a continuous decline of PCT concentrations to 430% from peak
values per day indicates significant improvement of systemic inflammation. Currently accepted cut-off reference values for
PCT concentrations are summarized in Table 1.
Specifically, PCT is ubiquitous and produced in the C cells (parafollicular cells) of the thyroid gland as a pro-hormone of
calcitonin (CT) and cleaved by intracellular proteolytic enzymes into the active hormone [3]. It is released by parenchymal
cells, including liver cells, kidney cells, adipocytes, and muscle cells in response to endotoxin or mediators released during
bacterial infections (e.g. interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and IL-6) [8]. Since PCT secretion into serum most
likely derives from neuroendocrine cells in the lungs or intestine as part of the systemic inflammatory response, it has been
termed a “hormokine” [9–11]. In contrast to cytokines, PCT release is more tightly controlled and found in the systemic
circulation alone during response to severe stress and sepsis [4,12,13]. During homeostasis, PCT circulates at very low levels,
whereas in bacterial infections, serum PCT levels start to rise at 4 h after the onset of systemic infection, and peak at 6 h,
maintaining a plateau between 8 and 24 h [14]. Circulating PCT levels halve daily when the infection is controlled by the
host immune system or antibiotic therapy [15].
Due to its peculiar biologic profile and “hormone-kine like” behavior PCT has been demonstrated to be a much more
refined and reliable indicator of infection than other markers currently available, featuring a higher sensitivity and speci-
ficity to other markers such as such as C-reactive protein (CRP), cytokines (IL-6, IL-8, IL-10) and lactate [9,16–20].
In addition to being used as a diagnostic marker, the measurement of PCT concentration is increasingly being used as part
of antimicrobial stewardship activities to monitor progression of infection and to begin/suspend antibiotic therapy [21,22].
To date, several commercial quantitative and qualitative PCT assays are available with different detection limits. The aim
of the present study was to analyze the discrimination ability of the LIAISON
s
BRAHMS PCT
s
II GEN (DiaSorin, Saluggia,
Italy) in healthy subjects and patients with suspected infection and compare the diagnostic performance of LIAISON
s
BRAHMS PCT
s
II GEN to the reference method B R A H M  S PCTs KRYPTOR (Thermo Fisher Scientific Clinical Diagnostics,
Hennigsdorf, Germany).2. Patients and methods
2.1. Study population
A total of 193 samples obtained from patients hospitalized at Vicenza Hospital (Italy) in September 2014 and previously
tested with the reference method B R A H M  S PCTs KRYPTOR, were tested with LIAISONs BRAHMS PCTs II GEN. They
were 112 men with a mean age of 67 years and 81 women with a mean age of 64 years. To validate the sensitivity and
specificity of the LIAISONs BRAHMS PCTs II GEN method, a population of adults and children were prospectively analysed:
311 adult patients and 243 children were enrolled. Out of 311 adult specimens, 150 were collected from apparently healthy
subjects from a European blood bank and 161 were hospitalized patients from the Chivasso Hospital (Italy). Baseline and
demographic patients data are not available. A group of 243 healthy outpatient children, 122 boys and 121 girls aged 1–12
years, with no clinical or biological sign of infection and no evidence of endocrine disorders, from microbiology laboratories
of the Area Vasta Romagna (AVR, Italy) were enrolled. Subjects positive for IgM or monitored for maternal infection were
excluded. These samples were collected to ensure that both genders and two age classes (1–6 years and 7–12 years) were
represented adequately.
2.2. Sample handling
PCT quantification was carried out on both serum or plasma. The manufacturer has confirmed equivalence between
serum, lithium heparin plasma, citrate plasma and EDTA plasma [23]. We measured the PCT levels in sera of the both
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Vicenza Hospital (Italy) were collected in lithium-heparin tubes, centrifuged and separated; they were stored at 18 °C,
then thawed and tested with the reference method (B R A H M  S PCTs KRYPTOR) and with LIAISONs BRAHMS PCTs II
GEN. The samples from healthy children (243 samples, Area Vasta Romagna), those from healthy adults (150 samples from
blood bank) and those from hospitalized adults (161 samples, Chivasso Hospital) were collected in serum tubes, centrifuged
and separated, stored at 18 °C, then unfrozen and tested with LIAISONs BRAHMS PCTs II GEN.
2.3. PCT measurement
For the 193 selected samples, LIAISON
s
BRAHMS PCT
s
II GEN determinations were compared with the concentrations
obtained from the B R A H M  S PCTs KRYPTOR assay, considered the reference assay in most studies for determining PCT
levels in plasma.
Both PCT methods are automated homogeneous sandwich immunoassay based on antibodies against the CP and kata-
calcin domains (CCP-I) of the prohormone: in particular, they use a sheep polyclonal anti-calcitonin antibody and a
monoclonal anti-katacalcin antibody, whereby the PCT molecules are bound by these 2 antibodies.
Briefly, the B R A H M  S PCT KRYPTOR assay is based on TRACE technology (time-resolved amplified cryptate emis-
sion), while the LIAISON
s
BRAHMS PCT
s
II GEN system is a chemiluminescence immunoassay (CLIA) technology with
paramagnetic microparticle solid phase.
Essentially, TRACE technology relies on measurement of the nonradioactive energy transfer from a donor molecule to an
acceptor molecule. In the KRYPTOR assay, the donor molecule is a europium cryptate-labeled polyclonal sheep antibody that
recognizes epitopes in the immature CP region of PCT, and the acceptor molecule is an XL665-labeled monoclonal antibody
against the CCP-I region of PCT. If PCT is present in the sample, it is sandwiched between the two molecules forming an
immunocomplex enabling a transfer of energy between the 2 tracers, donor and acceptor molecules, accompanied by an
amplification.
In the LIAISON
s
BRAHMS PCT
s
II GEN system the two different highly specific monoclonal antibodies are used for the
coating of the solid phase (magnetic particles, mouse monoclonal anti- katacalcin antibody) and for the tracer, labeled with
isoluminol, mouse monoclonal anti-calcitonin antibody. The intensity of the signal, and hence the amount of isoluminol-
antibody conjugate, is measured by a photomultiplier as relative light units (RLU).
The manufacturer claims intra-assay coefficients of variation (CV)o5% and inter-lot CVs between 4.4% and 17.6%.
In addition, the manufacturer claims that both assays are unaffected by human calcitonin and katacalcin levels, even at
high concentrations; no cross-reactions were observed [23]. The assay performance is also claimed not to be influenced by
conjugated and unconjugated bilirubin, hemoglobin or triglycerides [23].
The main characteristics of the two assays are summarized in Table 2. Specifically, the KRYPTOR method has a measuring
range of 0.02–1000 ng/mL, a functional sensitivity (20% total CV) of 0.06 ng/mL and a time to the first result of 19 min.
Whereas, the time for the first result of the LIAISON
s
BRAHMS PCT
s
II GEN method is 16 min with a measuring range of
0.02–100 ng/mL and a functional sensitivity of 0.04 ng/mL.
Functional sensitivity of the assay, described also as the Limit of Quantification (LoQ), is defined as the lowest analyte
concentration that can be determined with an inter-assay coefficient of variation (CV)o20%; the Limit of Detection (LoD),
defined also as analytical sensitivity, is the lowest analyte concentration likely to be reliably distinguished from the Limit of
Blank (LoB) (the highest apparent analyte concentration expected to be found when replicates of a blank sample containing
no analyte are tested) and at which detection is feasible; thus LoD is determined by utilizing both the measured LoB and test
replicates of a sample known to contain a low concentration of analyte. These factors have been established following the
Clinical and Laboratory Standards Institute (CLSI) guideline EP17-A [24].
All assay methods are based on an internal master curve with 1-point and 2-point calibration, respectively for KRYPTORTable 2
Main characteristics of assays BRAHMS PCT
s
KRYPTOR and LIAISON
s
BRAHMS PCT
s
II GEN.
Property BRAHMS PCT
s
KRYPTOR
LIAISONs BRAHMS
PCT
s
II GEN
Sample volume 50 μl 100 μl
Time for the first
result
19 min 16 min
Measuring range 0.02–1000 ng/mL 0.02–100 ng/mL
Calibration 1 point 2 point
Calibration stability 7 days 8 weeks
Integral on board
stability
14 days 12 weeks
Functional assay
sensitivity
0.06 ng/mL 0.04 ng/mL
LoD 0.02 ng/mL 0.02 ng/mL
Matrix Serum/plasma Serum/plasma
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s
BRAHMS PCT
s
II GEN assay. As a point of reference, a healthy individual's baseline PCT level, typically of
0.1 mg/mL, is used.
2.4. Statistical analyses
The analyses were carried out using Deming regression analyses, Spearman's correlation coefficient and Bland-Altman
difference plot to compare the two different measurement methods, and agreement at the clinically relevant cut-off was
calculated with kappa statistic. The level of statistical significance was set at pr0.05. As a useful complementary plot to
Bland–Altman, a mountain plot was also performed. This plot allows the comparison of 2 or 3 laboratory assays. A mountain
plot (or “folded empirical cumulative distribution plot”) is created by computing a percentile for each ranked difference
between a new method and a reference method. To obtain the plot, the following transformation is performed for all
percentiles above 50: percentile¼100percentile. These percentiles are then plotted against the differences between the
two methods [25]. The mountain plot was used because it makes it easier to find the central 95% of the data, even when the
data are not normally distributed.3. Results
The defined cut-off for exclusion of bacterial infections and sepsis is the PCT concentration of r0.2 ng/mL [4]. High PCT
levels have a high positive predictive value to rule in the diagnosis of sepsis (PCT 40.5 to 42 ng/mL), whereas normal or
very low PCT plasma concentrations have a high negative predictive value to rule out severe systemic inflammation or
sepsis (PCT o0.25 to o0.5 ng/mL).
The diagnostic performance of LIAISON
s
BRAHMS PCT
s
in measuring PCT level was assessed in comparison with the
reference method.
PCT levels were measured both with LIAISON
s
BRAHMS PCT
s
II GEN and B R A H M  S PCTs KRYPTOR reference
method in 193 selected samples, covering the assay reading range, in order to compare the two different assays. As shown in
Fig. 1, an excellent correlation (correlation coefficient, r¼0.99, obtained by linear regression analysis) both in term of slope
and intercept was obtained: a slope of Deming fit equal to 1.04 (95% CI: 0.99–1.09) with an intercept of 0.05 (95% CI: 0.09
to 0.19) (Fig. 1).
The graphs in Fig. 2 show that there are very small differences at very low concentrations which are of no clinical
significance.
A good correlation between the two methods was observed also in terms of clinical classification as indicated in Table 3.
In particular, the percentage of concordance between the two assays using a cut off of 0.5 ng/mL is 98.4% (95% CI: 95.5–
99.7%) as reported in Table 4.
To assess the utility and clinical value of LIAISON
s
BRAHMS PCT
s
II GEN in measuring PCT for diagnosis and to evaluate
its performance in patients without apparent infection, prospective samples from 311 adults and 243 children were ana-
lysed. Since PCT diagnostic indications in children are similar to those for adults, the pediatric population was enrolled with
the aim to implement and corroborate the specificity of the method utilized. The results are summarized in Table 4: none of
the samples of the 150 apparently healthy adult population showed a PCT concentration 40.5 ng/mL cut-off value—the
highest PCT value reported being equal to 0.033 ng/mL (95th percentile as well as 97.5th percentile lower than 0.02 ng/mL);
only 2 samples among the 161 hospitalized patients exhibited PCT concentration 40.5 ng/mL—with the highest value being
0.715 ng/mL (95th percentile: 0.054 ng/mL; 97.5th percentile: 0.088 ng/mL); and 3 samples of the healthy childrenFig. 1. BRAHMS PCT
s
KRYPTOR vs LIAISON
s
BRAHMS PCT
s
II GEN correlation (r¼0.99).
Fig. 2. (a) Bland-Altman plot comparing the two methods; and (b) mountain plot [25].
Table 3
Comparison of the two PCT measuring methods using a cut off of 0.5 ng/mL.
BRAHMS PCT
s
KRYPTOR Total
o0.5 ng/mL Z0.5 ng/mL
LIAISONs
BRAHMS
PCT s II
GEN
o0.5 ng/mL 101 1 102
Z0.5 ng/mL 2 89 91
Total 103 90 193
Table 4
Classification concordance between LIAISON
s
BRAHMS PCT
s
II GEN and B R A H M  S PCTs KRYPTOR.
Agreement (%) 95% CI (%)
o0.5 ng/mL 98.1 (101/103) 93.2–99.8
Z0.5 ng/mL 98.9 (89/90) 94–100
Total 98.4 (190/193) 95.5–99.7
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0.155 ng/mL; 97.5th percentile: 0.275 ng/mL).
Despite the lack of a counterpart hospitalized children population, we selected this pediatric population, with no clinical
or biological sign of infection, to emphasize the performance of the LIAISON
s
BRAHMS PCT
s
II GEN in evaluating normal PCT
levels. As reported in Table 5, only 5 samples from this population showed a PCT concentration 40.5 ng/mL. Specifically,
3 samples among the healthy children population and 2 samples in hospitalized patients' population resulted over
0.5 ng/mL. These samples were re-tested using Vidas Brahms PCTs, with comparable results (Table 6).
Table 5
PCT measurement in healthy and hospitalized study patients prospectively analysed by LIAISON
s
BRAHMS PCT
s
II GEN indicating 95th and 97.5th centiles
of the distribution.
Subjects N Mean
dose
(ng/mL)
95th
(ng/mL)
97.5th
(ng/mL)
40.5 ng/mL
Healthy
adults
150 o0.020 o0.020 o0.020 0
Healthy
children
243 o0.020 0.155 0.275 3
Hospitalized
adults
161 o0.020 0.054 0.088 2
Table 6
Samples with PCT concentration 40.5 ng/mL re-tested using Vidas Brahms PCTs.
ID LIAISON
s
Brahms
(ng/mL)
VIDAS Brahms
(ng/mL)
Hospitalized 1 0.69 0.57
Hospitalized 2 0.56 0.52
Children 1 0.50 0.46
Children 2 0.71 0.60
Children 3 0.55 0.53
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Currently, there are several different assays available for PCT measurement. This study compared the performance of the
LIAISON
s
BRAHMS PCT
s
II GEN system, a chemiluminescence immunoassay (CLIA) technology, with the reference method
BRAHMS PCT
s
KRYPTOR assay which is based on TRACE technology, and highlights the quality of LIAISON
s
BRAHMS PCT
s
II
GEN system in terms of sensitivity and specificity, both in adults and children populations.
The LIAISON
s
BRAHMS PCT
s
II GEN assay showed a good correlation and concordance with the reference method, which
is highly relevant for the routine implementation of PCT. In addition, this implies that switching from one assay to the other
should not have a clinically relevant influence on comparing data between the LIAISON
s
and the KRYPTOR assay.
The LIAISON
s
BRAHMS PCT
s
II GEN assay could also represent a key component for PCT-guided antibiotic therapy and for
use in the early diagnosis of severe bacterial respiratory tract infection, offering a fast, precise and reliable measurements of
PCT. However, as for the other commercially available PCT measurement assays, results must be interpreted carefully in the
context of medical history, physical examination and microbiological assessment, because increased PCT levels may not
always be related to infection, and low PCT levels do not automatically exclude the presence of bacterial infection. Therefore,
clinicians should use the PCT results in conjunction with the patient's other laboratory findings and clinical signs.
In summary, our results, although derived from relatively small groups of patients, confirm the utility of LIAISON
s
BRAHMS PCT
s
II GEN assay as a sensitive method for PCT determination.Disclosures
The present study did not rely on any external funding sources.References
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